Or wait…

Bio Developments
Upstream Processing
Downstream Processing
Markets & Regulations
Biopharma Culture
Promotional Features
Site Archive
Hot Topics
Antibody-Drug Conjugates
Emerging Markets
Cell & Gene Therapies
Site Archive
Type of resources
All Events
Online Events
Editorial Webinars
Shows & Conferences
Related Site
By Jane Byrne contact
05-Oct-2022 – Last updated on 14-Oct-2022 at 13:50 GMT
Related tags: Novo nordisk, Diabetes, Insulin
function sanitize_gpt_value2(gptValue)
var vOut = “”;
var aTags = gptValue.split(‘,’);
var reg = new RegExp(‘\W+’, “g”);

for (var i=0; i < aTags.length; i++)
vOut += aTags[i].trim().replace(reg, '-').substring(0,40);
if (i!=(aTags.length-1))
vOut +=', ';

vOut = vOut.toLowerCase();
return vOut;

$(document).ready(function() {
dataLayerNews = {};

dataLayerNews.related_tags = sanitize_gpt_value2("Novo nordisk, Diabetes, Insulin");

The Danish pharma group said it expects to file for regulatory approval of once-weekly insulin icodec in the US, the EU and China in the first half of 2023.
Novo Nordisk has announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes, a 52-week study comparing once-weekly insulin icodec with once-daily basal insulin.
The objective of the study was to assess the effectiveness and safety of insulin icodec, with an app providing dosing recommendation, in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting.
The trial included no upper limit in terms of hemoglobin A1c (HbA1c) levels at time of inclusion, no limitations on use of oral antidiabetic treatments and fewer planned site visits compared to the other ONWARDS phase 3a trials.
The study achieved its primary endpoint, said the developer. It demonstrated non-inferiority in reducing HbA1c at week 52 with insulin icodec compared with once-daily basal insulin analogues.
From an overall baseline HbA1c of 8.9%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of –1.68%-points compared with –1.31%-points for the once-daily basal insulins.”
In the trial, there was no statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia (blood glucose below 3 mmol/L) with 0.19 events per patient-year exposed to once-weekly insulin icodec and 0.14 events per patient-year exposed to the once-daily basal insulins. And the once-weekly insulin icodec appeared to have a safe and well-tolerated profile in the participants, said the Danish company.

“These results include real-world elements and a dosing guide app, which help us better understand how insulin icodec can make a difference for patients in a clinical practice setting,”​ said Martin Holst Lange, executive vice president for development, Novo Nordisk.
The results confirm the findings of previously reported ONWARDS trials and highlight that insulin icodec has the potential to be an ideal insulin for people with type 2 diabetes, he added. “We now look forward to sharing the results with regulatory authorities.”
Novo Nordisk has long been a pioneer in terms of innovation in the diabetes treatment space, Mads Frederik Rasmussen, senior vice president of clinical drug development at that pharma giant, told this publication in February.
And he explained then why the company’s once-weekly Insulin icodec injection represented a new treatment paradigm for diabetes:
“Insulin first started being produced for the treatment of diabetes 100 years ago. Since then, there have been many large and small steps forward in innovation, such as the first purified insulin, going from animal-based to human insulin, the invention of insulin analogues with faster or longer action and the development of increasingly convenient delivery solutions. Each of these steps have helped ensure that people with diabetes have been able to live longer and have a better quality of life, but we also know that not all people with diabetes are in good glycemic control. We believe that our investigational weekly insulin icodec has the potential to offer a new standard of care in this space.”
The ONWARDS program for once-weekly insulin icodec comprises six phase 3a global clinical trials, including a trial with real-world elements, involving more than 4,000 adults with type 1 or type 2 diabetes.
Besides the ONWARDS 5 trial, the program includes the following studies:
Copyright – Unless otherwise stated all contents of this web site are © 2022 – William Reed Ltd – All Rights Reserved – Full details for the use of materials on this site can be found in the Terms & Conditions
Related topics: Markets & Regulations
Show more
On-demand webinars


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *